Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Towards Personalized Management.
Sandy FengJohn C BucuvalasGeorge V MazariegosJohn C MageeAlberto Sanchez-FueyoKatharine M SpainAndrew LesniakSai KanaparthiEmily PeritoVeena L VenkatBryna E BurrellEstella M AlonsoNancy D BridgesEdward DooNitika A GuptaRyan W HimesDavid IkleAnnette M JacksonSteven J LobrittoJuan Jose LozanoMercedes MartinezVicky L NgElizabeth B RandAverell H SherkerShikha S SundaramYumirle P TurmelleMichele Wood-TrageserAnthony J DemetrisPublished in: Hepatology (Baltimore, Md.) (2020)
Immunosuppression withdrawal showed that 37.5% of selected pediatric liver transplant recipients were operationally tolerant. Allograft histology did not deteriorate for either tolerant or non-tolerant subjects. The timing and reversibility of failed withdrawal justifies future trials exploring the efficacy, safety, and potential benefits of immunosuppression minimization.
Keyphrases